Volitionrx Limited (VNRX) Issues Business Review 2024

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year.

Volition's major achievements in 2024 include:

• Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 20 countries worldwide.
• Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.
• Hosted Satellite Symposium at European Society of Intensive Care Medicine 2024 showcasing Nu.Q® NETs clinical utility in over 3,000 intensive care sepsis patients.
• Continued to strengthen our strategic patent portfolio.
• Made significant progress across a number of clinical and research programs within our cancer pillar.
• Initiated commercial discussions with significant players in the diagnostic space for both human and animal health out-licensing opportunities in large markets such as sepsis and oncology liquid biopsy. Information is being shared via virtual data rooms.
• Strengthened the Board of Directors in the appointment of an experienced chair, Timothy Still, and Independent Director, Dr. Ethel Rubin, both of whom bring significant commercial and financing experience in the diagnostic sector.

To find out more about these achievements, please read Volition's Business Review HERE

Cameron Reynolds, President and Group Chief Executive Officer, said: "As we head into 2025, Volition is at a pivotal juncture, ready to revolutionize the diagnosis and monitoring of life-altering diseases for both animals and humans.

"There is significant interest in potential licensing and/or supply agreements for both Nu.Q® NETs and our oncology portfolio, with several commercial discussions progressing well. We anticipate adding a number of clinical papers to our licensing data rooms early in 2025.

"Our team's dedication remains steadfast: driving progress across all our pillars, fostering clinical collaborations, achieving revenue growth and out-licensing our technologies. With a solid foundation, a focus on financial sustainability, and a clear vision for 2025, we are committed to fulfilling our mission of improving health outcomes for humans and animals worldwide."

You May Also Be Interested In

• Sparton, Glen Eagle ink joint venture deal for Ontario silver mine
• Broadcom (AVGO) call put ratio 1.3 calls to 1 put into quarter results
• Credo Tech (CRDO) call put ratio 1 call to 1 put into quarter results